Special Issue

Clinical Updates for Gastrointestinal Malignancies

Message from the Guest Editors

Gastrointestinal (GI) cancers encompass malignancies that can affect several organs of the digestive tract: the pancreas, stomach, liver, small and large intestines, colon, rectum, anus, and the biliary system. Notably, colorectal cancer and gastric cancer are the third and fifth most frequent types of cancer, respectively and are amongst the fifth most common causes of cancerrelated death worldwide. The treatment options for GI cancers depend on the tumor type and stage, and may include surgery, radiation therapy, chemotherapy, targeted therapy, and immunotherapy. In particular, recently, there have been notable advancements in the development of innovative treatments for GI cancers, such as targeted therapy and immunotherapy. The main objective of this Special Issue is to provide a comprehensive overview of the current advancements in diagnostic and therapeutic strategies, and a better prognostic stratification for GI cancers with the goal of advancing knowledge and improving patient outcomes.

Guest Editors

Dr. Carmelo Laface

Medical Oncology, Dario Camberlingo Hospital, 72021 Francavilla Fontana, Italy

Dr. Riccardo Memeo

Unit of Hepato-Pancreatic-Biliary Surgery, "F. Miulli" General Regional Hospital, 70021 Acquaviva Delle Fonti, Italy

Deadline for manuscript submissions

closed (31 March 2024)



Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/182251

Journal of Personalized Medicine Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jpm@mdpi.com

mdpi.com/journal/ jpm





Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. JPM publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). JPM is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).

